Search
Texas Life Science Forum: Mongoose Bio is advancing a novel TCR-T program that was developed at MD Anderson and plans to take it into the clinic next year
CEO Neil Warma describes the unique approach to TCRs that could reduce toxicity and increase persistence compared to other programs....
Nov 7, 2024
Texas Life Science Forum: NKILT Therapeutics is emerging into the in-vivo proof of concept stage of testing its HLA-G targeting cell therapy
CEO Raphaël Ognar describes the progress his company has made over the last year and previews data it will be presenting at SITC and ASH....
Nov 7, 2024
BioHouston CEO Ann Tanabe kicks off the 2024 Texas Life Science Forum
From the largest conference for life sciences in Texas each year, she describes the significant growth in infrastructure, startups,...
Nov 7, 2024
BIO-Europe: Mendus is developing cancer immunotherapies that focus on dendritic cell biology - an AML program will have a data update at #ASH24
CEO Erik Manting describes the rationale for focusing on dendritic cell biology, and covers previous data the company has presented in...
Nov 5, 2024
BIO-Europe: Pareto Securities' Biotech Analyst Dan Akschuti shares his thoughts on the conference and discusses recent company successes in the nordic region
He says there has been an upswing in investors looking at companies. Plus, his thoughts on BioInvent, Oculis, and Camurus. Brought to you by
Nov 5, 2024
BIO-Europe: Karolinska Institutet professor and physician Anna Wedell discusses the work she is doing and what areas of research excite her today
She discusses building systems around early diagnostics and treatment, rare disease discovery, mitochondrial disease and the brain,...
Nov 5, 2024
BIO-Europe: Centauri Therapeutics is planning to use antibody recruiting sugars that are linked to a targeting agent to treat infectious disease and cancer
CEO Jennifer Schneider describes how these "Alphamers" are designed to work and discusses the company's upcoming plans to enter the...
Nov 5, 2024
BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology
Executive Chairman Alexander Gebauer describes this approach to aiming to prevent toxic amyloid beta clumps from developing in the first...
Nov 5, 2024
BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year
CEO Mark Gaffney describes the science behind the lead program, CAL101, which targets a Damage Associated Molecular Pattern protein...
Nov 5, 2024
BIO-Europe: Dicot Pharma's CEO talks about moving the company's ED candidate into a phase 2a in multiple nordic countries - plus a stock market uplisting
Elin Trampe describes the unmet need the company believes exists for ED today, the history of their drug and how it was invented in...
Nov 4, 2024
BIO-Europe: The CEO of Sweden's Affibody on trying to be better than antibodies, moving into the radiopharmaceutical space, and IPO rumors
David Bejker describes how affibody's are meant to compete with monoclonal antibodies, which the company's lead program in IL-17. Plus,...
Nov 4, 2024
BIO-Europe: The CEO of Flerie, a publicly traded life sciences investment firm, discuses the firm's investment strategy and the health of biotech in the region
Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as...
Nov 4, 2024
BioVenture VoiCes Episode 5: KdT Ventures' Founder and Managing Partner Cain McClary
He describes this path to venture investing from his start in science at the NIH to becoming a pathologist, and eventually raising a...
Nov 4, 2024
BIO-Europe: Spain's Integra Therapeutics announced today that it has licensed novel Cas12l nucleases from Lithuania-based Caszyme as it continues to develop its gene writing platform
Integra CEO Avencia Sánchez-Mejías and Caszyme CEO Monika Paulė discuss the deal and explain why Cas12l's small size gives it...
Nov 4, 2024
BIO-Europe: Sweden's Alligator Bioscience is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward
CEO Søren Bregenholt describes this program, and why Alligator chose pancreatic cancer. Plus, he discusses CD40 x CEA(CAM5) and 4-1BB x...
Nov 4, 2024
BIO-Europe: Germany based HepaRegeniX is targeting MKK4 to spur regeneration in diseased livers. This year the company has published clinical data and raised a series C
CEO Elias Papatheodorou describes the unmet need in liver disease and the rationale for MKK4, a target HepaRegeniX is focused on and is...
Nov 4, 2024
Dallas based Etira is aiming to cause apoptosis in cancer cells by targeting LIPA and thus inducing stress in the endoplasmic reticulum
CEO Russell Hayward describes the scientific rationale of this approach, as well as how the company may be weeks away from dosing its...
Oct 30, 2024
A UT Southwestern neurology expert and the CEO of GenrAb discuss neuro-immunology and finding antibodies that can help with neuronal damage
UTSW's Dr. Ben Greenberg discusses how neuro-immunology is making inroads for conditions like MS, ALS, and alzheimer's. GenrAb CEO Larry...
Oct 30, 2024
The CEO of the nonprofit MassChallenge describes the way it supports startups and entrepreneurs, and why it has chosen Dallas as its second region of major focus in the U.S. outside of Boston
Cait Brumme highlights MassChallenge's equity-free model and how it helps biotech entrepreneurs from the earliest stages to understanding...
Oct 30, 2024
Biotech entrepreneur RA Session II describes converting science from UT Southwestern into companies - he currently has a new one that is in stealth mode
Having been involved with Reata, Taysha Gene Therapies (founder), ReCode Therapeutics and more, RA has a good handle on the biotech scene...
Oct 29, 2024
.png){kind=logo}
